SiBone (NASDAQ:SIBN) Director Mika Nishimura Sells 4,100 Shares of Stock

SiBone (NASDAQ:SIBN) Director Mika Nishimura sold 4,100 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $13.83, for a total value of $56,703.00. Following the completion of the sale, the director owned 32,716 shares of the company’s stock, valued at approximately $452,462.28. This represents a 11.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

SiBone Trading Down 5.6%

Shares of SIBN opened at $13.05 on Friday. The stock’s 50-day moving average is $16.28 and its two-hundred day moving average is $16.72. The stock has a market cap of $576.42 million, a PE ratio of -29.66 and a beta of 0.69. SiBone has a 12 month low of $12.49 and a 12 month high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.55 and a quick ratio of 7.21.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. The business had revenue of $56.35 million during the quarter, compared to analyst estimates of $56.26 million. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%. Equities analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SiBone

Several hedge funds and other institutional investors have recently bought and sold shares of SIBN. First Light Asset Management LLC boosted its stake in shares of SiBone by 162.4% during the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock valued at $99,249,000 after buying an additional 3,115,001 shares during the last quarter. American Century Companies Inc. increased its stake in shares of SiBone by 22.5% in the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after buying an additional 521,683 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of SiBone by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock worth $49,331,000 after buying an additional 11,566 shares during the last quarter. Nuveen LLC raised its holdings in SiBone by 5.1% in the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after acquiring an additional 69,229 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its stake in SiBone by 17.1% during the 4th quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock valued at $23,664,000 after acquiring an additional 175,000 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SIBN. Truist Financial reiterated a “buy” rating and set a $24.00 price objective (up from $23.00) on shares of SiBone in a research note on Tuesday, February 24th. Needham & Company LLC upped their target price on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Morgan Stanley raised their price target on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Canaccord Genuity Group lifted their price target on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and an average target price of $24.67.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.